🔗 Share this article

A shadow economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Investigational Treatment Gaining Popularity Via Social Media

The experimental drug, which remains in research studies, is being advertised by online personalities for its supposed fat-burning properties. Followers are encouraged to message these accounts directly for source information, while also receiving promotional offers.

Active Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where groups with thousands of participants share “before and after” images, administration instructions and assertions of rapid British shipping. Sellers market the substance there before redirecting customers to WhatsApp for transactions.

Understanding The Experimental Drug

This medication is an experimental injection created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Professionals Voice Concerns

However, doctors and chemists have cautions that the sale of what is still an unlicensed drug in the UK is worrisome and could result in users administering products of unknown origin.

Some experts said the popularity for retatrutide could be linked to the increasing price of approved slimming treatments such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate pharmaceutical, advertising, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.

Service Reaction and Content Removal

Based on TikTok, the service has removed problematic content and banned related hashtags and search suggestions. The company stated it was committed to maintaining the platform safe and investing in enhancing compliance measures.

Online Marketplace Operations

Research also found communities with up to 9,000 participants selling retatrutide using Telegram's built-in search feature, which functions like a online catalog. Entering “retatrutide” instantly displays channels with numerous of members, populated with photos of slimming results, glowing reviews and detailed instructions for mixing or administering at home.

Within moments of joining one group, a seller shared contact information, where most purchases take place. The seller provided an guidebook and guaranteed delivery within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None asked about weight, health issues or previous experience.

Product Details and Pricing

Within these groups, messages show dark colored parcels with Royal Mail stickers, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with sterile water, or ready-to-use pens usually sold at 160 pounds for 20 milligrams. When questioned how much time a injector should be used, vendors give contradictory responses ranging from a several days to “depends on your body”.

Platform Oversight and Security Measures

A representative for the messaging service stated it regularly monitored dangerous material on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are injecting substances they cannot confirm. Although the science behind this drug is valid, these digital products may not include what they advertise,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the increase in interest to current cost increases for authorized weight-loss medications such as Mounjaro. “With prices rising, patients are using online platforms. But counterfeit injections are highly dangerous. You cannot know what’s contained or whether the environment they were produced in was clean,” she said.

Her staff has already encountered individuals harmed by personal administration from unconfirmed sources. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These substances could be contaminated or improperly measured.”

Manufacturer Position

A representative from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental product not yet authorized … may subject patients to possibly significant medical dangers”.